Primary Immune Thrombocytopenia Clinical Trials

73 clinical trials for Primary Immune Thrombocytopenia across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP) — RECRUITING · PHASE1
• Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab — RECRUITING · PHASE2
• SG301-SC Injection Safety Study in Subjects With Primary ITP Patients — RECRUITING · PHASE2
• A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) — RECRUITING · PHASE2
• Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia — RECRUITING · PHASE2
• A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia — RECRUITING · PHASE3
• High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia — RECRUITING · PHASE3
• Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults — RECRUITING · PHASE4
• A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia — RECRUITING · PHASE3
• An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia — RECRUITING · PHASE3
• Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) — RECRUITING · PHASE1
• Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) — RECRUITING
• Safety Study of CC312 in Autoimmune Disease Patients — RECRUITING · PHASE1
• Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial — RECRUITING · PHASE2
• A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia — RECRUITING · PHASE3
• RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia — RECRUITING
• Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. — RECRUITING · PHASE1
• Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP — RECRUITING · PHASE2
• A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP — RECRUITING · PHASE2
• Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia — RECRUITING · PHASE3
• Study to evaluate the efficacy and safety of human immune globulin in patients with primary immune thrombocytopenia — COMPLETED · PHASE3
• C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA — TERMINATED · PHASE2
• A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) — NOT_YET_RECRUITING · PHASE3
• rhTPO Dose Escalation vs Eltrombopag Switch in ITP — NOT_YET_RECRUITING · NA
• A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. — NOT_YET_RECRUITING · PHASE2
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids — ACTIVE_NOT_RECRUITING · PHASE3
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — ACTIVE_NOT_RECRUITING · PHASE3
• Phase III Study on HMPL-523 for Treatment of ITP — COMPLETED · PHASE3
• A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies — ACTIVE_NOT_RECRUITING · PHASE2
• Managed Access Programs for VAY736, Ianalumab — OTHER
• A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had insufficient response or relapsed after first line steroid treatment (VAYHIT2) — TERMINATED · PHASE3
• A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). — COMPLETED · PHASE3
• A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI — TERMINATED · PHASE2
• A multicentre, randomized, open-label study of romiplostim plus dexamethasone vs dexamethasone in patients with newly diagnosed primary immune thrombocytopenia — TERMINATED · PHASE3
• Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy — NOT_YET_RECRUITING · PHASE2
• A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia — TERMINATED · PHASE3
• Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP) — COMPLETED
• A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia — ACTIVE_NOT_RECRUITING · PHASE3
• ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia — OTHER · PHASE3
• Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP — NOT_YET_RECRUITING · PHASE4
• The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) — WITHDRAWN · PHASE1
• A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults — NOT_YET_RECRUITING · PHASE2
• Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia — COMPLETED · PHASE2
• A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY — NOT_YET_RECRUITING · PHASE2
• Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) — TERMINATED · PHASE3
• A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). — COMPLETED · PHASE3
• Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia — OTHER · PHASE1
• A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia — COMPLETED · PHASE3

Refine this search